Published in Oncogene on July 18, 2011
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist (2013) 1.41
The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget (2012) 0.94
PPARs Signaling and Cancer in the Gastrointestinal System. PPAR Res (2012) 0.83
The role of peroxisome proliferator-activated receptors in colorectal cancer. PPAR Res (2012) 0.81
Targeting peroxisome proliferator-activated receptor-β/δ in colon cancer: how to aim? Biochem Pharmacol (2012) 0.78
IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol (2002) 7.23
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med (1998) 5.16
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 5.12
Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem (2001) 4.21
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol (2000) 3.37
Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res (2001) 3.29
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med (1998) 2.90
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology (2003) 2.65
Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60
Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell (2002) 2.50
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res (2000) 2.32
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A (2001) 2.06
A p34(cdc2) survival checkpoint in cancer. Cancer Cell (2002) 1.99
The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci (2000) 1.93
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med (2004) 1.89
Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A (2006) 1.84
Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem (2004) 1.72
Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res (2005) 1.68
Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology (1996) 1.65
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat (2003) 1.60
Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther (2006) 1.57
Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat (2002) 1.49
Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol (2006) 1.49
Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol (2001) 1.48
Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem (2001) 1.48
Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res (2000) 1.43
Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res (2005) 1.35
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J (2002) 1.33
PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene (2006) 1.28
PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther (2005) 1.28
Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer (2006) 1.26
The anti-apoptotic role of PPARbeta contributes to efficient skin wound healing. J Steroid Biochem Mol Biol (2003) 1.19
Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst (2009) 1.16
Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun (2003) 1.12
Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J Biol Chem (2004) 1.11
Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem (2005) 1.10
Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer (2006) 1.09
Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem (2002) 1.09
Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther (2003) 1.03
Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. Br J Cancer (2006) 0.94
Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPARgamma agonists and a structurally unrelated PPARgamma agonist. Toxicol Pathol (2004) 0.87
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69
The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2000) 5.18
PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol (1998) 5.01
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 4.59
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med (2000) 4.18
Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science (1999) 3.98
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 3.13
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
Projections of the medial and lateral prefrontal cortices to the amygdala: a Phaseolus vulgaris leucoagglutinin study in the rat. Neuroscience (1996) 3.01
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors. Proc Natl Acad Sci U S A (2001) 2.77
Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone (2004) 2.75
Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem (1997) 2.66
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev (1999) 2.37
The heat capacity of proteins. Proteins (1995) 2.37
Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet (1998) 2.31
LAI inversion algorithm based on directional reflectance kernels. J Environ Manage (2006) 2.31
Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1. Nat Genet (1999) 2.28
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Rho3 of Saccharomyces cerevisiae, which regulates the actin cytoskeleton and exocytosis, is a GTPase which interacts with Myo2 and Exo70. Mol Cell Biol (1999) 2.15
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther (2001) 2.13
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
Oral topical decontamination for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Hosp Infect (2013) 2.05
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res (2000) 2.05
Estimation of changes in side chain configurational entropy in binding and folding: general methods and application to helix formation. Proteins (1994) 1.97
Regulation of expression of IL-4 alleles: analysis using a chimeric GFP/IL-4 gene. Immunity (2001) 1.97
GP73, a novel Golgi-localized protein upregulated by viral infection. Gene (2000) 1.96
Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. J Immunol (2001) 1.93
Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol (1996) 1.91
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene (2010) 1.85
Internal lysine palmitoylation in adenylate cyclase toxin from Bordetella pertussis. Science (1994) 1.78
Coi1-dependent expression of an Arabidopsis vegetative storage protein in flowers and siliques and in response to coronatine or methyl jasmonate. Plant Physiol (1995) 1.77
Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem (2000) 1.77
Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology (2000) 1.75
Risk factors for oesophageal cancer in northeast China. Int J Cancer (1994) 1.73
Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J Natl Cancer Inst (1997) 1.67
Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry (1997) 1.66
Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology (1996) 1.65
Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol (1997) 1.63
Structural energetics of peptide recognition: angiotensin II/antibody binding. Proteins (1993) 1.58
Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem (2000) 1.58
EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene (2011) 1.56
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol (2013) 1.48
Polycystin-2 is a novel cation channel implicated in defective intracellular Ca(2+) homeostasis in polycystic kidney disease. Biochem Biophys Res Commun (2001) 1.48
Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem (2001) 1.48
Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene (2006) 1.45
Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation. J Biol Chem (2001) 1.43
High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer (2005) 1.42
Bayesian analysis of pentaquark signals from CLAS data. Phys Rev Lett (2008) 1.39
Entropy in biological binding processes: estimation of translational entropy loss. Proteins (1994) 1.39
Measurement of two- and three-nucleon short-range correlation probabilities in nuclei. Phys Rev Lett (2006) 1.37
A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology (1997) 1.35
The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer (1995) 1.32
A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1. Kidney Int (2008) 1.30
Molecular basis of co-operativity in protein folding. III. Structural identification of cooperative folding units and folding intermediates. J Mol Biol (1992) 1.29
Segmentation of touching cell nuclei using gradient flow tracking. J Microsc (2008) 1.28
Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem (2001) 1.28
lambda-Repressor oligomerization kinetics at high concentrations using fluorescence correlation spectroscopy in zero-mode waveguides. Biophys J (2004) 1.28
Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest (1997) 1.25
Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer (2008) 1.24
Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem (1998) 1.24
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog (1999) 1.23
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res (1997) 1.23
Estimation of the risk of bloodborne pathogens to health care workers after a needlestick injury in Taiwan. Am J Infect Control (2002) 1.23
Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology (1998) 1.22
Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system. Proc Natl Acad Sci U S A (1996) 1.21
Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene (2001) 1.20
Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem (2001) 1.20
Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys (1995) 1.20
Epitope mapping of monoclonal antibodies against Bordetella pertussis adenylate cyclase toxin. Infect Immun (1999) 1.19
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia (2001) 1.18
Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis (1998) 1.16
Transient inhibition of interleukin 4 signaling by T cell receptor ligation. J Exp Med (2000) 1.16
Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci (1998) 1.15
DLK1: increased expression in gliomas and associated with oncogenic activities. Oncogene (2006) 1.15
Endovascular stenting of extracranial carotid artery aneurysm: a systematic review. Eur J Vasc Endovasc Surg (2011) 1.14
A nosocomial outbreak of KPC-2-producing Klebsiella pneumoniae in a Chinese hospital: dissemination of ST11 and emergence of ST37, ST392 and ST395. Clin Microbiol Infect (2013) 1.14
Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma. Oncogene (2010) 1.14
Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis (2010) 1.13
Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology (2000) 1.13
Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses. Neurochem Int (2001) 1.13
Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem (1992) 1.12
Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology (1998) 1.11
Hemolytic, but not cell-invasive activity, of adenylate cyclase toxin is selectively affected by differential fatty-acylation in Escherichia coli. J Biol Chem (1995) 1.10
Body mass index and injury risk among US children 9-15 years old in motor vehicle crashes. Inj Prev (2008) 1.10
Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res (1998) 1.09
Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol (1997) 1.09
Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem (2000) 1.09
Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. Mol Pharmacol (2000) 1.09
Posttranslational modifications within the HIV-1 envelope glycoprotein which restrict virus assembly and CD4-dependent infection. AIDS Res Hum Retroviruses (1991) 1.08
Acceleration of purine degradation by periodontal diseases. J Dent Res (2009) 1.08
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis (1999) 1.07